gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BFRIHealthcarePharmaceuticals

Biofrontera Inc. Common Stock (BFRI)

$0.9038+1.56%
Close Nov 4, 2026 · split-adjusted
Nov 2, 2026$0.88▼ 19.78% in range
Nov 3, 2025Low $0.57 · High $1.61Nov 2, 2026
What changed · written from our data
As of Nov 4, 2026

Biofrontera closed at $0.90 on Nov 4, up 1.56%, 43.9% below its 52-week closing high. Volume of 194.3K shares was 1.06× its 20-day average (close to normal).

Split-adjusted performance: -3.0% over one month, -20.7% over six months, -17.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $12M, up 32.9% from a year earlier, with a net margin of -5.0%.

Short interest was 103.1K shares at the Oct 15 settlement, down 29.8% from the prior report (0.9% of float, 1.0 days to cover).

Market cap$13.4M14.9M shares
Revenue · quarter$12.0M+32.9% YoY
Diluted EPS$-0.05—
P/E · TTM—P/S 0.3×
Net margin-5.0%Gross 79.9%
Dividend yieldNone
52-week range0.57 – 1.61−43.9% from high
Volume194.3K1.06× 20-day avg
Volatility · 60d76.0%Annualised
Short % of float0.9%1.0 days to cover
Net cash$47.0KCash $4.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +2.0%1M −3.0%3M −27.7%6M −20.7%YTD +58.6%1Y −17.8%3Y −76.2%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum56
Revenue growth72
Net margin66
Value (low P/E)—
Size18

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short103.1K−29.8% vs prior
Days to cover1.0Settled Oct 15
% of float0.9%
Short vol. 10d48.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BFRIBiofrontera$0.9038+1.56%−20.7%+32.9%−5.0%—$13.4M
DAREDare Bioscience$0.6619+1.83%−79.1%—−1590.4%—$13.0MCompare
AEONAEON Biopharma$0.2086−1.70%−77.0%———$12.3MCompare
HINDVyome Holdings$1.74−1.93%−21.1%—−2543.3%—$12.2MCompare
CTXRCitius Pharmaceuticals$0.5510−3.87%−17.3%—−593.3%—$15.1MCompare
LPCNLipocine$1.44−1.37%−40.7%−100.0%——$11.9MCompare
BOLTBolt Biotherapeutics$6.54−0.46%+42.5%−99.7%−154400.0%—$15.4MCompare
BIVIBioVie$1.34−22.54%−19.3%———$11.6MCompare
CLRBCellectar Biosciences INC NEW$1.23−6.11%−65.2%———$11.6MCompare

News about Biofrontera

All news →
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026GlobeNewswire Inc. · May 8, 2026Neutral

Quick answers

What does Biofrontera do?
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.
What is BFRI's market cap?
$13.42M, based on the Nov 4 close of $0.90.
Does Biofrontera pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BFRI is sold short?
103.1K shares, 0.9% of float, as of Oct 15, 2026.
What sector is BFRI in?
Healthcare, in the Pharmaceuticals industry.

About Biofrontera

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

HQ: Woburn, MA94 employeesListed Oct 29, 2021biofrontera-us.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology